Glycoxidative Stress and Cardiovascular Complications in Experimentally-Induced Diabetes: Effects of Antioxidant Treatment by Karasu, Çimen
240  The Open Cardiovascular Medicine Journal, 2010, 4, 240-256   
 
  1874-1924/10  2010 Bentham Open 
Open Access 
Glycoxidative Stress and Cardiovascular Complications in Experimentally-
Induced Diabetes: Effects of Antioxidant Treatment 
Çimen Karasu* 
The Leader of Antioxidants in Diabetes-Induced Complications (ADIC) Study Group. Cellular Stress Response & Signal 
Transduction Research Laboratory, Department of Medical Pharmacology, Faculty of Medicine, Gazi University,   
Ankara, Turkey 
Abstract: Diabetes mellitus (DM) is a common metabolic disease, representing a serious risk factor for the development 
of cardiovascular complications, such as coronary heart disease, peripheral arterial disease and hypertension. Oxidative 
stress (OS), a feature of DM, is defined as an increase in the steady-state levels of reactive oxygen species (ROS) and may 
occur as a result of increased free radical generation and/or decreased anti-oxidant defense mechanisms. Increasing   
evidence indicates that hyperglycemia is the initiating cause of the tissue damage in DM, either through repeated acute 
changes in cellular glucose metabolism, or through long-term accumulation of glycated biomolecules and advanced glyca-
tion end products (AGEs). AGEs are formed by the Maillard process, a non-enzymatic reaction between ketone group of 
the glucose molecule or aldehydes and the amino groups of proteins that contributes to the aging of proteins and to the 
pathological complications of DM. In the presence of uncontrolled hyperglycemia, the increased formation of AGEs and 
lipid peroxidation products exacerbate intracellular OS and results in a loss of molecular integrity, disruption in cellular 
signaling and homeostasis, followed by inflammation and tissue injury such as endothelium dysfunction, arterial stiffen-
ing and microvascular complications. In addition to increased AGE production, there is also evidence of multiple path-
ways elevating ROS generation in DM, including; enhanced glucose auto-oxidation, increased mitochondrial superoxide 
production, protein kinase C-dependent activation of NADPH oxidase, uncoupled endothelial nitric oxide synthase 
(eNOS) activity, increased substrate flux through the polyol pathway and stimulation of eicosanoid metabolism. It is, 
therefore, not surprising that the correction of these variables can result in amelioration of diabetic cardiovascular abnor-
malities. A linking element between these phenomena is cellular redox imbalance due to glycoxidative stress (GOS). 
Thus, recent interest has focused on strategies to prevent, reverse or retard GOS in order to modify the natural history of 
diabetic cardiovascular abnormalities. This review will discuss the links between GOS and diabetes-induced cardiovascu-
lar disorders and the effect of antioxidant therapy on altering the development of cardiovascular complications in diabetic 
animal models. 
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INTRODUCTION 
  In the past few decades, diabetes mellitus (DM) has   
rapidly increased in the world. It has been estimated that the 
number of diabetic patients will more than double within 20 
years. DM is mainly characterized by the development of 
increased morbidity and mortality due to cardiovascular   
disease (CVD) [1-3]. Diabetic cardiovascular complications 
appear to be multifactorial in origin, but in particular, gly-
coxidative stress (GOS) has been suggested to be the unify-
ing link between the various molecular disorders in DM. The 
biochemical process of advanced glycation end products 
(AGEs), is accelerated in DM due to chronic hyperglycemia-
induced oxidative stress (OS), which has been postulated to 
play a central role in this disorder [4-6]. DM has been sug-
gested to be a major source of AGEs in vivo [7]. The   
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consequences of GOS include; damage to DNA, lipids,   
proteins, disruption in cellular homeostasis and accumulation 
of damaged molecules. These damaged molecules disrupt 
endothelial cells and cardiomyocytes and impair cardiovas-
cular reactivity [7]. Nitric oxide (NO) regulates vasodilata-
tion, anticoagulation, leukocyte adhesion, smooth muscle 
proliferation and the antioxidative capacity of endothelial 
cells [8]. Hyperglycemia has been reported to decrease the 
availability of NO in animals and humans, which may con-
tribute to the hemodynamic and physiological changes oc-
curring in DM [9]. G protein-adenylyl cyclase signaling, 
diacylglycerol (DAG)/ protein kinase C (PKC) pathway and 
calcium current/ entry, which play an important role in the 
regulation of cardiovascular functions has also been reported 
to be impaired in diabetes-induced GOS [10]. The harmful 
effects of hyperglycemia-induced GOS on cardiovascular 
function and the link to pathophysiological mechanisms   
underlying diabetic complications have lead to the develop-
ment of new pharmacotherapeutic strategies. Although,   
aldose reductase inhibitors and PKC inhibitors represent   
a potential therapeutic approach to prevent the onset or   
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focused on strategies to prevent firstly GOS and then its 
harmful effects [11, 12]. Indeed, there is accumulating   
evidence that an interaction between AGE and its receptor 
(RAGE) generates OS and subsequently evokes vascular 
inflammation and thrombosis, thereby playing a central role 
in diabetic vascular complications [13]. This review presents 
evidence of the pathophysiology and cellular mechanisms of 
cardiovascular complications in experimental DM; discuss 
the therapeutic strategies with antioxidant compounds and 
evaluates the pyridoindole derivatives as potential remedy 
for diabetes-induced metabolic, structural and functional 
abnormalities in the cardiovascular system. 
EXPERIMENTAL DIABETES-INDUCED CARDIO-
VASCULAR COMPLICATIONS 
The Mechanisms of Abnormal Cardiac Contractility in 
DM 
  Patients with DM are more prone to develop cardiomy-
opathy than nondiabetic subjects [14]. This complication is 
serious and is a major cause of mortality due to DM. Accord-
ing to the Framingham study, the incidence of cardiovascular 
morbidity per year is 39.1% in diabetic males and 17.2% in 
diabetic females; chronic heart failure afflicts 7.6% of dia-
betic males and 11.4% of diabetic females. Diabetic cardio-
myopathy is a specific syndrome, consisting of cardio-
megaly, left ventricular dysfunction, electrical remodeling of 
the ventricle, and symptoms of congestive heart failure [15, 
16]. Hypertension is recognized as an important cofactor in 
the development of fatal congestive heart failure in diabetics 
[17]. The pathophysiology of diabetic cardiomyopathy is 
incompletely understood and several mechanistic approaches 
are under debate. Decreased left ventricular compliance and 
increased interstitial connective tissue have been observed in 
chronically diabetic animals [17]. In contrast, ventricular 
myocardium from diabetic rats exhibit a reversible decrease 
in the speed of contraction, prolongation of contraction, and 
a delay in relaxation [17, 18]. These mechanical changes are 
associated with changes in the responses to alpha- and beta-
adrenergic and cholinergic stimulation [18]. We have shown 
that the changes in myocardial beta-adrenergic responsive-
ness may contribute to heart failure in streptozotocin (STZ)-
diabetic rats [19]). Both insulin-dependent diabetes mellitus 
(IDDM) [20] and non-insulin-dependent diabetes mellitus 
(NIDDM) [21] causes significant alterations in myocardial 
contractility induced by adrenergic agonists. In our labora-
tory, it has been showed that experimental diabetes produces 
a marked decrease in the rate of spontaneously beating right 
atria and a significant increase in basal contractile force of 
left ventricular papillary muscle. In diabetic rat atria, the 
positive chronotropic effect of noradrenaline was markedly 
increased, while the positive chronotropic effect of isoprena-
line was significantly decreased. STZ-diabetes also induced 
an increased positive inotropic response of papillary muscle 
to both noradrenaline and isoprenaline [19, 21]. In addition, 
the ultrastructural degeneration of the diabetic myocardium 
(i.e. intracellular oedema, myofibrillar fragmentation, con-
densed pleomorphic mitochondria, thick capillary irregular 
basement membrane and swollen endothelial cells) was as-
sociated with mechanical alterations caused by adrenergic 
agonists [21]. Long-term experimental IDDM, characterized 
by ventricular remodeling, overt resting left ventricular sys-
tolic dysfunction and decreased left ventricular responsive-
ness to beta-adrenergic receptor stimulation is associated 
with histopathological changes indicating dilatational re-
modeling as increased capillary tortuosity and type IV colla-
gen in capillaries and cardiomyocytes [22]. Insulin replace-
ment therapy in STZ-diabetic rats can prevent these changes 
[19, 20], and thyroid hormones mediate the effect of insulin 
therapy [19]. These findings were recently confirmed in a 
study using conscious diabetic rats, which showed a decrease 
in basal mean arterial pressure, heart rate, +dP/dtmax and -
dP/dtmax. In that study, insulin prevented the hemodynamic 
and myocardial function alterations observed in STZ-
diabetic rats [23]. Another study indicated that male and fe-
male rats are affected differently by DM in terms of left ven-
tricular developed pressure (LVDP) responses to beta-
adrenergic receptors (beta-ARs) stimulation, probably due to 
the difference between their beta-ARs induced cyclic adeno-
sine monophosphate (cAMP) responses [24]. Alterations in 
the myocardial beta-AR signaling pathway in two different 
models of rat NIDDM, has also been addressed; it showed 
that the beta-AR signaling system of the insulin deficient 
model is altered more than the hyperinsulinemic model and 
the exaggerated cAMP response of NIDDM [25, 26]. Hearts 
from diabetic db/db mice, a model of NIDDM, exhibited left 
ventricular failure and altered metabolism of exogenous sub-
strates, was prevented by PPAR-alpha and -gamma agonists 
[27]. Diabetic cardiomyopathy was expressed by a decreased 
beta1-AR mRNA levels, and an increased beta2- and beta3-
ARs mRNA levels in STZ-treated diabetic rat hearts [28, 
29]. Insulin-deficient diabetes was associated with a reduced 
expression and concomitant functional loss of G inhibitor 
protein in ventricular cardiomyocytes [30]. Long-term DM 
results in a marked decrease in the positive inotropic re-
sponse of left atria to electrical field stimulation due to the 
impairment of noradrenaline release from sympathetic nerve 
terminals [31]. On the other hand, it has been shown that an 
alpha-adrenergic receptors (alpha-ARs)-mediated electro-
physiological response is unmasked when the beta-AR-
mediated response is desensitized in the papillary muscle of 
STZ-induced diabetic rats [32]. Alpha1-adrenergic respon-
siveness of rat myocardium was reported to be higher in ex-
perimental diabetes and partly reversed by insulin treatment 
[32]. This increase has been suggested to serve as a compen-
satory mechanism for the lower beta-adrenergic responsive-
ness in this organ [32]. The results showed that diabetes-
induced impairment in cardiac alpha 1-AR signaling is 
closely linked with the abnormal activation of cardiac PKC 
[33, 34]. Other studies also indicated that presynaptic alpha 
2-ARs and muscarinic receptors that are linked to the inhibi-
tion of noradrenaline release during nerve stimulation are 
functionally impaired in diabetic animals [30]. 
  The altered cholineacetyltransferase, cholinesterase ac-
tivities and choline concentration has been suggested to be 
the reasons for the supersensitivity to muscarinic agonists in 
the myocardium of STZ-diabetic rats [35]. In addition, car-
diac M2-muscarinic receptor (M2-MR) gene expression was 
increased in STZ-diabetic rats [35, 36]. Alterations in the 
atrial muscarinic system in STZ-diabetic rats have been sug-
gested to be a consequence of impaired functional mus-
carinic receptor-G protein coupling [37, 38]. In fact, aldose 
reductase inhibitors have been successfully used to treat and 
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in experimental DM [35]. In the light of previous reports, 
diabetes-induced functional abnormalities in the heart may 
be attributed to altered adenosine action. The purinergic re-
sponse of rat atria was increased in STZ-diabetes [39]. It has 
been demonstrated that the changes in adenosine receptor 
gene expression and protein content correlated with some of 
the abnormalities characterized in the diabetic heart [39]. An 
increase in adenosine A1 receptor protein content, without a 
change in mRNA level was observed in isolated cardiac 
myocytes. DM caused an increase of adenosine A3 receptor 
mRNA and protein content in the heart and cardiac   
myocytes. The level of adenosine A2a receptor mRNA was 
increased in the whole diabetic heart, but it decreased in   
cardiac myocytes with undetectable changes in protein   
content. Interestingly, the administration of insulin to diabetic 
rats for four days resulted in the adenosine receptors, mRNA 
and protein content returning to levels observed in the heart 
of normal rats [39, 40]. 
  Hyperglycemia-induced up-regulation of the endothelin 
(ET)-system is another important event in the pathogenesis 
of diabetic CVD. The measurement of ET-1, ET (A) and ET 
(B) receptors and mRNAs showed a significant increase in 
mRNA levels in the hearts of diabetic rats. ET-1 was de-
tected in the cardiomyocytes, endothelium and smooth mus-
cle cells of the larger blood vessels by immunohistochemis-
try, which diabetes increased. Autoradiographic localization 
of ET-1 receptors showed increased binding in the endothe-
lium and myocardium of diabetic animals [41]. ET-1 was 
also elevated in atherosclerotic plaques. Diabetic patients 
have accelerated atherosclerosis and also show elevated 
plasma levels of ET-1. Inhibiting the actions of ET-1 and the 
signaling pathways are thought to represent potential thera-
peutic targets for the prevention of atherosclerotic diabetic 
disease [42]. 
  Metabolic impairment such as hyperglycemia, hyperlipi-
demia, hypoinsulinemia, and alterations in cardiac metabo-
lism are the main reasons for vascular structural and func-
tional changes, which instigate the cellular effects leading to 
redox imbalance, interstitial fibrosis, myocyte death, and 
disturbances in ion transport and homeostasis [43]. A de-
crease in myosin ATPase, a shift in myosin isoenzyme dis-
tribution, alterations in a variety of Ca
2+ fluxes associated 
with cardiac mechanical alterations are observed in experi-
mental DM [44]. A deficiency in sarcoplasmic reticulum 
Ca
2+ uptake contributes to a lower beta-ARs-stimulated 
inotropic response of diabetic myocardium [45]. Chronic 
STZ-diabetes leads to Ca
2+ accumulation in cardiac myo-
cytes [46]. In accordance with this, the changes in intracellu-
lar Ca
2+ mobilization has been suggested to account for the 
depressed IGF-I-induced inotropic response in the diabetic 
heart [47]. Indeed, alterations in intracellular Ca
2+ handling 
play a pivotal role in the impairment of cardiac function in 
diabetes. The reduced function of the sarcoplasmic reticulum 
Ca
2+-ATPase and Ca
2+-release in response to beta-AR chal-
lenge, is thought to have a causative role in the depressed 
hemodynamic performance of the challenged heart in the 
early stage of DM [47]. The observed changes in the con-
tractility, together with Ca
2+ handling of the diabetic heart 
are most likely attributable to functional disturbances of 
SERCA2a, RyR2 and NO/ cyclic guanosine monophosphate 
(cGMP) systems in response to beta-adrenergic activation 
[48,49]. The changes in cardiac mechanical parameters cor-
relate with decreased ATP and increased lactate in the inner 
layer of the left ventricle in diabetic rats. But, of course, this 
cannot be explained by the rate of decrease in total ATP and 
lactate accumulation alone [50]. Recent evidence implicates 
disturbances in cardiac energy metabolism; in the uncon-
trolled diabetic state, cardiac myocytes use fatty acids almost 
exclusively to support ATP synthesis [51].  
IMPAIRED VASCULAR REACTIVITY IN DM: ROLE 
OF ENDOTHELIAL CELLS 
  Vascular disease, a complicating feature of DM, is char-
acterized mainly by atherosclerotic and coronary artery ab-
normalities [52]. Diabetic patients have a 2- to 4-fold in-
crease in the incidence for coronary artery disease and 10-
fold increase in peripheral vascular diseases, due in part, to 
accelerated atherogenesis [53]. Alterations of vascular 
smooth muscle function have been widely implicated in the 
development of vascular complications and circulatory dys-
function in DM [54]. However, the influence of DM on 
catecholamine-induced vasopressor activity under in vitro 
conditions is contradictory. Although, a decreased respon-
siveness of the rat aorta to noradrenaline and phenylephrine 
has been noted in STZ-diabetes [55-57], many investigators 
have demonstrated an increased responsiveness of the rat 
aorta to alpha-AR stimulation in the same model [58, 59]. 
Similarly, we found an increased responsiveness of isolated 
aorta to alpha-AR agonists in rats with at least six weeks 
diabetes, which was reversed by insulin treatment [60-64]. 
The duration of DM might be the main reason for this dis-
crepancy [65, 66]. Our observations using diabetic rat aorta 
were subsequently confirmed by the finding of an increase in 
the contractility of the internal mammary artery and saphe-
nous vein obtained from diabetic patients undergoing coro-
nary artery bypass surgery [67]. The increased responsive-
ness of the diabetic aorta to vasoconstrictor agents was asso-
ciated with the abnormal structure of the smooth muscle and 
endothelial cells [62, 63].  
  We demonstrated that the entry of Ca
+2 into the cytosolic 
membrane of diabetic rat aorta was augmented by the in-
creased activation of voltage (L-type) and receptor-operated 
channels, since there was an increased contraction to L-type 
Ca
2+ channel activator BayK-8644 and AR-receptor agonist 
phenylephrine [68, 69]. Moreover, Ca
2+ overload and/or   
impaired Ca
2+,Mg
2+-ATPase activity might also been re-
sponsible for these abnormalities [45]. Indeed, other investi-
gators suggested that changes in functional Ca
2+ store sizes 
and the Ca
2+ entry seems to be responsible for the alterations 
in contractile responses to phenylephrine following DM   
[65, 70]. In fact, diabetes-induced contractile disturbances 
are not only related to the activity of Ca
2+ channels or Ca
2+ 
current but also the involvement of K
+ channels. A dimin-
ished relaxation response to cromakalim, a KATP channel 
opener, has been reported in diabetic vessels by us, as well 
as others [71-73]. 
  In 1980, Furchgott discovered that vascular endothelial 
cells produce an endothelium-derived relaxing factor 
(EDRF) in response to stimulation by ACh [74]. Vascular 
relaxation to ACh and a number of other agonists was found 
to be dependent on the presence of an intact endothelium. In 
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that EDRF is NO [75, 76]. A year later, Moncada also dem-
onstrated that NO is synthesized from the amino acid L-
arginine [77]. Earlier, Murad had shown that the relaxing 
effect of nitrovasodilators depended on the activation of 
soluble guanylate cyclase to increase cGMP levels in the 
arteries [78]. All these works have contributed to the estab-
lishment of NO as a signaling molecule in the cardiovascular 
system. In 1992, NO was described as the molecule of the 
year [79] and the importance of the NO discovery was rec-
ognized with the Nobel Prize in Physiology and Medicine 
awarded to Furchgott, Ignarro and Murad. Subsequently, NO 
had been implicated in the pathogenesis of diseases such as 
DM, atherosclerosis and hypertension. Today, it is hard to 
find a disease which is not associated with altered NO ho-
meostasis. In 1989 it was reported that endothelial cells con-
tain a cytosolic enzyme that is directly or indirectly regulated 
by Ca
2+, which converts L-arginine into a compound that 
stimulates guanylate cyclase and behaves similarly to EDRF 
[80]. In the same year we reported, for the first time, that 
endothelium-dependent relaxations produced by ACh and 
histamine in aortic rings precontracted with noradrenaline 
was significantly increased in 6 weeks STZ-induced, IDDM 
[60]. In contrast, the relaxations elicited by those agents 
were significantly attenuated in aorta of NIDDM rats. [60]. 
Previously, an attenuated response of isolated aorta to endo-
thelium-dependent vasodilators had been reported by Oyama 
et al. in STZ-diabetic rats [81] and by Durante et al. in Bio 
Bred (BB) rats [82]. However, we found that the abnormal 
endothelial function in diabetic aorta was especially depend-
ent on hyperglycemic control and the duration of DM [61, 
62]. 
  Over the years, many investigators have demonstrated 
some abnormalities in endothelium-dependent relaxation in 
arteries from a number of experimental animal models of 
DM [83-87], while others have found no changes in response 
to endothelium-dependent vasodilators [88]. In this context, 
the endothelium of diabetic aorta exhibits decreased, in-
creased or unchanged responsiveness to ACh depending on 
the model, severity and/or duration of DM [88]. Now, endo-
thelium-dependent vasodilatation is recognized as a repro-
ducible and accessible parameter to probe endothelial func-
tion in different pathophysiological conditions, including 
DM, aging and CVD. Similarly, we confirmed endothelial 
dysfunction in studies of human NIDDM [67]. The impaired 
endothelium-dependent vasodilatation might arise from de-
creased NO production, enhanced inactivation of NO, im-
paired diffusion of NO to the underlying smooth muscle 
cells, decreased responsiveness of the smooth muscle to NO 
and enhanced generation of endothelium-derived constrict-
ing factors. As a common observation, we and many others 
reported that the relaxation of diabetic aorta induced by so-
dium nitroprusside (an endothelium-independent and cGMP-
mediated relaxant agent) was comparable to control tissue, 
suggesting that vascular smooth muscle exhibit a normal 
responsiveness to a guanylate cyclase stimulator such as NO, 
in the diabetic state [60-62, 84, 85]. Despite a growing un-
derstanding of the mechanisms by which NO is released 
from the endothelium, the precise molecular mechanisms by 
which NO relaxes vascular smooth muscle are not fully un-
derstood. Previous studies have provided evidence that a 
major action of NO in normal vascular smooth muscle is to 
reduce intracellular free Ca
2+ levels via cGMP-dependent 
and-independent mechanisms. It was also proposed that NO 
can activate SERCA by a cGMP-independent process   
[89, 90]. NO influences vascular homeostasis in many ways 
beyond modulation of vasomotion, such as inhibition   
of smooth muscle cell proliferation, platelet aggregation, 
platelet and monocyte adhesion to the endothelium, LDL 
oxidation, expression of adhesion molecules and endothelin 
production [91]. 
  Besides cyclooxygenase and nitric oxide synthase (NOS), 
another distinct endothelial pathway is endothelium-
dependent hyperpolarization (EDHF), which is also involved 
in the relaxation of the vascular smooth muscle cells. EDHF 
has been demonstrated unequivocally in various blood ves-
sels from different species, including human and is likely to 
play an important role in cardiovascular physiology. This 
alternative pathway involves the activation of two popula-
tions of endothelial K
+ channels, the small conductance and 
intermediate conductance Ca
2+-activated K
+ channels, which 
are altered in DM [92, 93]. On the other hand, the interaction 
between endothelial cells and monocytes is thought to play 
an important role in normal vascular biology, while an in-
creased/prolonged interaction is implicated in the pathogene-
sis of vascular disease [91]. Monocyte adhesion to the endo-
thelium suppresses the release of biologically active NO in 
monocyte in a concentration-and time-dependent manner, 
via an IL-1 dependent pathway [91, 94]. This event would 
predispose the vessel to develop atherosclerotic lesions due 
to the potential consequence of increased macromolecular 
permeability and intimal proliferation via the development of 
vasospasm, thrombosis and recruitment of platelets and leu-
kocytes [91, 94]. In this respect, we confirmed the monocyte 
adhesion to the endothelial cells and impaired morphology of 
diabetic aorta by electron microscopy [63, 64, 68, 95]. Beside 
monocytes, there are many other inhibitors of the biological 
activity of NO, such as decreased L-arginine uptake,   
decreased co-factors (Ca
2+, calmodulin, BH4), inhibition of 
electron flow (nicotinamide adenine dinucleotide phosphate; 
NADPH, flavins), inhibition of NOS expression, inhibition 
of substrate binding to NOS, and NO scavengers [97, 98]. 
GLYCOXIDATIVE STRESS IN THE NATURAL   
HISTORY OF DIABETES-INDUCED CARDIOVAS-
CULAR COMPLICATIONS 
  Although the mechanisms responsible for mediating en-
dothelial dysfunction have not been completely defined, ele-
vated OS plays a key role in the development of endothelial 
dysfunction, as well as, atherosclerosis in diabetes-associated 
vascular disease. Increased basal production of superoxide 
(O2
–), and hydrogen peroxide (H2O2) in the aorta has been 
shown in early studies using diabetic animals [98, 99]. The 
main reasons for the diabetes- induced increase in OS are; an 
increased generation of oxygen-derived free radicals through 
autoxidation of glucose, AGE-formation, increased substrate 
flux through the polyol pathway, and stimulation of eicosa-
noid metabolism, sorbitol-DAG metabolism and NOS [4-7, 
11, 13, 92, 96, 100, 101]. Glucose-induced changes in the 
activity of NADPH oxidase and endothelial nitric oxide syn-
thase (eNOS) can cause vascular endothelial cell dysfunction 
via disregulation of eNOS and/or changes in the expression 
of the subunits of NADPH oxidase [102]. Generally, the 
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insufficient removal of highly reactive molecules such as, 
reactive oxygen species (ROS) and reactive nitrogen species 
(RNS) [100-103]. ROS includes; free radicals such as O2
–, 
hydroxyl (OH), peroxyl (RO2), hydroperoxyl (HRO2
–), as 
well as, non-radical species such as H2O2 and hydrochlorous 
acid (HOCl). RNS include free radicals such as; NO and 
nitrogen dioxide (NO2
–), as well as non-radicals such as per-
oxynitrite (ONOO
–), nitrous oxide (HNO2) and alkyl   
peroxynitrates (RONOO). There are multiple sources of   
OS in DM, which include non-enzymatic, enzymatic and 
mitochondrial pathways [4-7, 11, 101, 103]. Non-enzymatic 
sources of OS originate from the oxidative biochemistry of 
glucose. Hyperglycemia can directly cause an increase in 
ROS generation. Glucose can undergo autoxidation and gen-
erate OH radicals [103]. In addition, glucose can react with 
proteins in a non-enzymatic manner leading to the develop-
ment of Amadori products followed by the formation of ad-
vanced glycation end-products AGEs; ROS is generated at 
multiple steps during this process. The formation of AGEs 
progressively increases with normal aging, even in the ab-
sence of disease. However, they are formed at an accelerated 
rate in DM due to uncontrolled hyperglycemia. DM is a ma-
jor source of AGEs production in vivo and is not only a 
marker but also an important causative factor for the patho-
genesis of the disease. AGE modification of proteins leads to 
alterations in their normal function, abnormal signal trans-
duction pathways and tissue injury all contribute to the de-
velopment of serious complications, which is responsible for 
the morbidity and mortality observed in diabetic patients [6, 
7, 12, 13, 104-106]. Binding and activation of cellular 
RAGE by AGEs or similar ligands can also promote OS and 
AGE formation via the NAD(P)H oxidase and the myeloper-
oxidase pathways. Another potential mechanism of AGE 
formation is the polyol pathway. Glucose entering the polyol 
pathway may form AGEs via reactive intermediates, i.e. 
glyoxal, methylglyoxal or 3-deoxyglucosone, as well as, via 
depletion of NAD(P)H or glutathione raising intracellular 
OS, all of which indirectly result in the increased formation 
of AGEs [104-106]. There are two types of cell surface AGE 
receptors, those that bind AGEs and initiate cell activation 
and those that bind and degrade AGEs. RAGE is the best 
studied receptor of the first category; it recognizes AGEs and 
initiates OS. The second group of receptors includes; 
AGER1, AGER3 and CD36. The best evaluated receptor in 
this category is AGER1, which has been found to have 
marked anti-oxidant properties [12, 13, 106, 107]. In the 
presence of chronic hyperglycemia, there is enhanced 
metabolism of glucose through the polyol (sorbitol) pathway, 
which also results in enhanced production of O2
– [106]. En-
zymatic sources for increased generation of ROS in DM in-
clude mainly NOS, NAD(P)H oxidase and xanthine oxidase 
[13,104,108,109]. All isoforms of NOS require five cofac-
tors/prosthetic groups such as flavin adenine dinucleotide 
(FAD), flavin mononucleotide (FMN), heme, BH4 and Ca
2+-
calmodulin. If NOS lacks its substrate L-arginine or one of 
its cofactors, NOS may produce
 O2
instead of NO and this  
is referred to as the uncoupled state of NOS [109, 110]. 
NAD(P)H oxidase is a membrane associated enzyme that 
consists of five subunits and is a major source of O2
– produc-
tion [109]. It has been demonstrated that the enhanced pro-
duction of O2
– in the diabetic vasculature, predominantly 
mediated by the increased levels of NAD(P)H oxidize also 
stimulates PKC activity [109]. It has been suggested that 
mitochondrial O2
– is the initiating “snowball” that turns OS 
into an avalanche in DM by stimulating more ROS and RNS 
production  via downstream activation of nuclear factor-
kappaB (NF-KB)-mediated cytokine production, PKC and 
NAD(P)H oxidase [111-113]. 
  In light of the OS hypothesis, we previously investigated 
the time course for changes in endothelium-dependent re-
laxations using isolated aorta rings. It was found that endo-
thelium-dependent and -independent relaxant responses of 
diabetic aorta are more transient than those of non-diabetic 
control vessels and the time required to reach peak relaxation 
after the addition of ACh was shorter in aortic rings isolated 
from 6-month STZ-diabetic rats compared to non-diabetic 
rats [114]. In our study, pretreatment of diabetic vessels with 
superoxide dismutase (SOD) normalized the recovery phases 
of endothelium-dependent and -independent relaxations, but 
had no effect on the peak responses to ACh and sodium ni-
troprusside. In the presence of diethyldithiocarbamate, an 
inhibitor of SOD, the transient nature of the relaxant re-
sponse to ACh or sodium nitroprusside was found to be more 
marked and the peak relaxations were inhibited; these effects 
of diethyldithiocarbamate were more pronounced in diabetic 
than in control rings. Catalase caused a decrease in the peak 
relaxant response to ACh and accelerated the fading of the 
relaxation in diabetic aorta. While, pretreatment with 3-
amino-1,2,4 triazole, (a catalase inhibitor), inhibited the peak 
relaxant response to ACh in diabetic rings. The combination 
of SOD plus 3-amino-1,2,4 triazole produced an increase in 
the transient nature of endothelium-dependent relaxation of 
diabetic aorta, which was greater than that with 3-amino-
1,2,4 triazole alone. Neither catalase nor 3-amino-1,2,4 tria-
zole affected the characteristics of sodium nitroprusside-
induced relaxation. Desferrioxamine, an inhibitor of OH 
radical production, or mannitol, a OH radical scavenger, had 
no effect on the characteristics of either ACh- or sodium 
nitroprusside-induced relaxation in control and diabetic aorta 
[114]. Similarly, others have reported that the rapid fade of 
the endothelium-dependent responses of diabetic vessels is 
significantly suppressed by pretreatment with SOD but not 
with catalase, deferoxamine, allopurinol, or indomethacin 
[115]. The OS-related rapid inactivation of NO has been 
recognized as an important factor leading to diabetes-
induced endothelial dysfunction [92, 114-117]. 
  We, as well as, others have found that the diabetic aorta 
is more sensitive to ROS exposure when compared to non-
diabetic, healthy aorta [118, 119]. H2O2 induced a brief con-
traction before relaxation of aorta rings with an intact endo-
thelium that was more pronounced in diabetic vessels. Re-
moval of the endothelium or pretreatment of the rings with 
L-nitro-arginine methyl ester (L-NAME), a NO synthase 
inhibitor, immediately abolished the H2O2-induced response 
with a transient increase in tone, while pre-incubation with 
indomethacin had no significant effect on aortic contractions 
induced by H2O2 in long-term diabetic and healthy control 
animals. In addition, long-term STZ-diabetes caused a sig-
nificant increase in the maximum relaxation induced by 
H2O2 in aorta already preconstricted with alpha-AR agonists. 
Preincubation with SOD had no effect on the maximum re-
laxation induced by H2O2, in both non-diabetic and diabetic 
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in non-diabetic rats. Aortic rings preincubated with dieth-
yldithiocarbamate; H2O2 produced only contractions in non-
diabetic rats, while H2O2-induced relaxations were markedly 
depressed in diabetic animals. Catalase did not affect the 
smooth muscle tone of intact or endothelium-denuded aortic 
rings, stimulated by H2O2 and aminotriazole failed to affect 
H2O2-induced contractions or relaxations of diabetic and 
non-diabetic vessels. These series of experiments suggest 
that long-term DM causes a decrease in vessel SOD activity 
that may lead to a change in the dismutation reaction of O2
 
to H2O2, causing an increase in endogenous O2
– anions. The 
diabetes-induced increase in catalase activity could account 
for the increased production of harmful OH in the aorta. The 
enhanced endogenous formation of OH might be an impor-
tant factor in the development of vascular disorders associ-
ated with chronic DM [118]. 
  The excessive production of O2
 in DM plays a signifi-
cant role in the inhibition of EDRF/NO bioavailability under 
basal physiological conditions. The increased vasorelaxation 
caused by exogenous stimulants of NOS in the early stages 
of experimental DM [60-62] might compensate for an envi-
ronment where the basal endothelial relaxation is decreased. 
Moreover, the involvement of endogenous H2O2 during 
ACh-stimulated endothelium-dependent relaxation might be 
increased, which is likely to account for the maintenance of 
the vasorelaxant effect of ACh in the later stage of DM. This 
phenomenon of an enhanced contribution of H2O2 in the es-
tablishment of stimulated endothelium-dependent relaxation 
could account for the maintenance of NOS-mediated relaxa-
tion in diabetic arteries [114, 118, 119], is also supported by 
Matoba et al. These authors reported that in some pathologi-
cal conditions eNOS generates O2
, which is converted by 
SOD to H2O2 facilitating endothelium-dependent relaxation 
[120]. It has also been reported that acute administration of 
scavengers of O2
, including SOD [113, 120], the combina-
tion of SOD with catalase [121] or OH radical scavengers, 
restored or normalized the abnormal endothelium-dependent 
responses in different models of DM [115, 121-123]. Never-
theless, an increased production of OH might also mediate 
the increased vasoconstriction tendency of diabetic vessels 
under basal condition. This is supported by the observation 
that OH can catalyze the production of vasoconstrictor 
prostanoids [122-124]. We subsequently revealed an in-
creased SOD-induced relaxation of diabetic aorta when 
compared with non-diabetic aorta. Pretreatment of aortic 
rings with L-NAME inhibited SOD-induced relaxation, 
which was greater in diabetic rings compared to control 
aorta. While, catalase inhibited SOD-induced relaxation only 
in diabetic rings. Pretreatment with the cyclooxygenase in-
hibitor, indomethacin, or the catalase inhibitor, aminotria-
zole, had no effect on SOD-induced relaxation in both con-
trol and diabetic vessels. These findings suggested that: (i) 
under normal physiological conditions, the relaxant effect of 
SOD is related to the inhibition of O2
-induced EDRF/NO 
destruction in the rat aorta; (ii) in the diabetic state, an excess 
of O2
 increasingly inhibits basal EDRF/NO, and exoge-
nously added SOD causing an enhancement of the dismuta-
tion reaction resulting in the excess O2
 forming H2O2. The 
production of H2O2, a vasorelaxant molecule, probably ac-
counts for the increased responsiveness of diabetic rings to 
exogenous SOD [119]. On the other hand, the responsive-
ness of the diabetic aorta may reflect an important facet of 
H2O2 linked to its specific modulatory role that might com-
pensate for an increase in vascular reactivity in response to 
alpha-AR stimulation due to OS. It is well known that the 
vasorelaxation of alpha-AR agonist-precontracted artery 
rings by H2O2 requires the formation of cGMP, and is medi-
ated by NO [125]. H2O2 also augments the secretion of other 
endothelium-derived relaxing peptides, e.g., adrenomodulin 
and C-type natriuretic peptide, which are thought to compen-
sate for vasoconstriction due to increased OS, in conditions 
such as, hypertension, atherosclerosis as well as DM [126]. 
In fact, under hyperglycemic conditions the excessive pro-
duction of O2
  interacts with the basal production of 
EDRF/NO, leading to an increase in the generation of the 
highly reactive molecule ONOO
. In this situation, the 
chemical environment of NO (i.e. an increase in O2
), may 
be a determining factor whether NO exerts protective or 
harmful effects [127]. Accordingly, it has been reported that 
a greater production of O2
 and a greater formation of nitrate 
(NO is metabolized by O2
 to NO3
) occurs in aortic rings 
from diabetic rats [128]. It is also known that ONOO
 can 
modify tyrosine residues in various proteins to form nitroty-
rosine, which can lead to damage that alters protein function 
and stability [128, 129]. Thus, nitrotyrosine is a marker of 
OS [129, 130], in diseases such as atherosclerosis, heart dis-
ease and DM [129]. Several studies have shown that the 
formation of nitrotyrosine and ONOO
 are factors in NO 
responsiveness and NO production in blood vessels [129, 
130]. In this regard, we compared the vasodilatory effect of 
exogenous ONOO
 with sodium nitrite in precontracted 
aorta isolated from STZ-induced diabetic and age-matched 
control rats [131]. ONOO
 produced a concentration-
dependent relaxation of aortic rings with/without endothe-
lium. Vasorelaxation occurred with higher concentrations of 
the decomposition product ONOO
 or sodium nitrite, al-
though these relaxations were considerably slower with re-
duced sensitivity. Endothelium intact rings were less sensi-
tive to the vasorelaxant effect of ONOO
 than endothelium-
denuded rings, in control but not in diabetic aorta. The 
maximum relaxation to ONOO
 was also increased in dia-
betic vessels, which was unaffected by the removal of the 
endothelium either in diabetic or control rings. DM did not 
alter the relaxations elicited by both decomposed ONOO
 
and sodium nitrite. ONOO
-induced relaxation was not in-
hibited by diethylenetriaminepentaacetic acid, an inhibitor of 
OH formation. While, pretreatment with ONOO
 signifi-
cantly suppressed the phenylephrine-induced tone and ACh-
stimulated endothelium-dependent relaxation; both effects 
were more pronounced in diabetic than in control aorta. 
Taken together, these findings suggest that there is a rela-
tionship between the increased responsiveness to exogenous 
ONOO
 and the depressed basal NO bioavailability in dia-
betic aorta [131]. The reported inhibitory effect of ONOO
 
on NO bioavailability and the elevation in endothelial dys-
function by angiotensin II in diabetic animals is consistent 
with the findings. Angiotensin II has been found to increase 
the generation of ROS within vascular smooth muscle cells, 
primarily through activation of membrane-bound NADPH/ 
NADH oxidase, which promotes a progressive deterioration 
of the cardiovascular system in STZ-induced diabetic rats 
[132, 133]. Diabetes-induced over production of angiotensin 
II may also in turn, trigger the dysfunction of vascular 
smooth muscle SERCA by the generation of ONOO
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In fact, the physiological actions of NO and O2
 may depend 
crucially on their local concentrations and their intracellular 
site of formation. In order to accumulate as H2O2, endothelial 
O2
 must first escape interacting with NO molecules; under 
normal conditions, at least in some blood vessels, it appears 
that a small amount of O2
 survives long enough to be acted 
upon by SOD to generate H2O2. However, under pathologi-
cal conditions, the production of O2
 (largely from sources 
other than eNOS) may overwhelm the production of NO in 
many blood vessels. Under these circumstances, H2O2 pro-
duction will be limited by the availability of SOD, and endo-
thelium derived ONOO
, prostanoids, and possibly iso-
prostanes may tip the balance toward vasoconstriction [92, 
124, 135]. 
  Although the mechanisms underlying diabetes-induced 
endothelial dysfunction are likely to be multi-factorial, in-
vivo and in-vitro studies indicate a crucial role for the DAG-
PKC pathway in mediating this phenomenon. PKC may have 
adverse effects on vascular function, including the activation 
of O2
-producing enzymes such as NADPH oxidase, as well 
as, increased expression of a dysfunctional O2
  producing 
uncoupled (eNOS III). PKC-mediated O2
 production may 
inactivate NO derived from eNOS III, and inhibit the activity 
and/or expression of the NO downstream target; soluble 
guanylyl cyclase [124, 135]. During the development of DM 
a number of biochemical and mechanical factors converge 
on the endothelium, resulting in endothelial dysfunction and 
vascular inflammation. Hyperglycaemia leads to increased 
formation of AGE, which quenches NO and impair endothe-
lial function. AGEs act directly to induce cross-linking of 
proteins such as collagen to promote vascular stiffness, and, 
thus, alter vascular structure and function. Receptor-
mediated actions of AGEs can induce intracellular signaling 
that leads to enhanced OS and increase key proinflammatory 
and prosclerotic cytokines [6, 7, 12, 104]. Increased vascular 
inflammation, including enhanced expression of interleukin- 
6 (IL-6), vascular cellular adhesion molecule-1 (VCAM-1) 
and monocyte chemoattractant protein (MCP-1) are observed, 
as is a marked decrease in NO bioavailability [136]. 
GLYCOXIDATIVE STRESS: A KEY THERAPEUTIC 
TARGET? 
The Role of Antioxidants in Prevention and Delaying 
Cardiovascular Complications Associated with   
Experimental DM 
  A possible target for the management of the multiple risk 
factors in diabetic CVD could be the treatment of endothelial 
dysfunction, since all the risk factors are related to endothe-
lial dysfunction [135-139]. As mentioned above, various 
interventions have proven effective in restoring impaired 
endothelium-dependent vasodilatation in certain vascular 
beds in animal and human DM. In this regard, optimizing 
eNOS function is a reasonable approach; this can be realized 
by using co-factors, e.g., BH4, L-arginine, or by increasing 
cGMP availability via phosphodiesterase type 5 (PDE5) in-
hibitors, or by enhancing eNOS expression. [138]. Several 
studies have reported on the modulating effect L-arginine 
supplementation has on diabetic in vivo NO production, un-
der conditions known to be associated with endothelial dys-
function [139]. Angiotensin-converting enzyme (ACE) inhi-
bition, which is conventionally used for the management of 
CVD, has been shown to; decrease angiotensin II-induced 
NADH oxidase activity and vascular production of O2
, to 
stimulate basal NO production by suppression of bradykinin 
breakdown or perhaps by potentiating the vascular effects of 
insulin [140]. In addition to ACE inhibitors, physical exer-
cise, calcium channel blockers and angiotensin II receptor 
antagonists have been found to ameliorate flow-evoked en-
dothelium-dependent vasodilatation in diabetic patients and 
animals [141]. We and others, showed an improvement in 
endothelium-dependent vasodilation, as well as, myocardial 
structure and function following the administration of   
lipid-lowering statins to diabetic rats [142, 143]. More   
recently, endothelin A receptor antagonists, atresantan or 1-
methylnicotinamide, a primary metabolite of nicotinamide 
preserved endothelium-dependent relaxation in diabetic   
vessels [144, 145]. Interestingly, a considerable body of evi-
dence suggests that increasing NO bioavailability via anti-
oxidant therapy is an important intervention not only for 
endothelial dysfunction but also other cardiovascular abnor-
malities induced by DM [22, 63, 68, 119]. 
  The inhibition of intracellular free radical formation 
would provide a therapeutic strategy to prevent OS and the 
related diabetic vascular complications. In this regard, the 
determination of ROS production is an important evaluation 
of the intracellular and extracellular redox balance and ho-
meostasis. It would be possible determine the level of ROS 
generating enzymes in the extracellular and intracellular 
compartments depending on location, e.g., NAD(P)H/NADH 
oxidase in the cell membrane, xanthine oxidase, myeloper-
oxidase, cytochrome P450 in cytoplasm, and mitochondrial 
oxidation and antioxidant enzymes such as, SODs, glu-
tathione peroxidase, heme oxygenase, thioredoxin peroxi-
dase/peroxiredoxin, catalase, and paraoxonase [112, 146]. 
Although there is controversy about the antioxidant status in 
DM, our biochemical measurements revealed that SOD ac-
tivity is inhibited in diabetic aorta together with the activa-
tion of catalase [114]. In addition to this, hearts from 12 
weeks diabetic animals showed about a four-fold increase in 
the level of thiobarbituric acid reactive substances (TBARS), 
indicative of increased lipid peroxidation. This was accom-
panied by approximately 100 % increase in both catalase and 
glutathione peroxidase (GSHPx) enzyme activities [147]. 
We have also found; increased GSHPx and catalase activity, 
decreased glutathione reductase (GR) activity and SOD ac-
tivity unchanged in the diabetic heart. The activity of pentose 
phosphate pathway enzymes, glucose-6-phosphate dehydro-
genase (G-6PD) and 6-phosphogluconate dehydrogenase (6-
PGD) were significantly decreased in diabetic aorta [148]. In 
an attempt to neutralise OS, cells utilize antioxidant defenses 
comprised of enzymatic and non-enzymatic compounds that 
determine redox balance. Enzymes include; SOD, catalase, 
thioredoxin, and GSHPx, while, non-enzymatic compounds 
include; glutathione, ascorbate, tocopherol and polyphenolic 
compounds [109, 149]. SOD immediately converts O2
– to 
H2O2, which is then detoxified to water either by catalase in 
the lysosomes or GSHPx, in the mitochondria. GR, which 
regenerates glutathione, is used as a hydrogen donor by 
GSHPx during the elimination of H2O2. Similarly, SOD and 
GSHPx expression/activities were decreased whereas; cata-
lase was increased in experimental models of DM [101, 150, 
151]. The modulation of these enzymes in target organs 
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beneficial in the prevention and management of heart failure. 
Accordingly, the use of gene transfer of extracellular SOD to 
study the endothelial effects of OS has recently been re-
ported. Gene transfer of normal extracellular SOD improved 
endothelial dysfunction in several disease states, thus, this 
technique may be useful to study the mechanism by which 
gene variants predispose vessels to endothelial dysfunction 
and vascular disease [152]. More recently, Tempol, a cell 
permeable SOD mimetic, was found to increase endothe-
lium-dependent vasodilatation in arteries from hypertensive 
animals, most likely through the lowering of ROS, making it 
a potential therapeutic tool for a disease characterized by 
decreased NO bioavailability [141]. 
  Several reports using experimental diabetic models have 
shown that improving glycemic control does not sufficiently 
improve the accompanying OS [153]. We found that in vivo 
insulin replacement therapy alone was unable to prevent or 
restore metabolic, functional and/or structural abnormalities 
in the heart and aorta of STZ-diabetic rats [19-21, 61, 62]. 
However, the combination of insulin with non-enzymatic 
antioxidants showed more effectiveness in the prevention 
and amelioration of vascular [154] and cardiac [147] abnor-
malities in STZ-diabetic rats. In this context, to avoid inter-
ference from glucose toxicity, the increased availability of 
AGE detoxification systems, which include; enzymatic 
mechanisms such as the glyoxalase-I and II system, anti-
oxidant defenses, circulating proteins that trap AGEs, recep-
tor-dependent intracellular uptake and destruction, as well 
as, urinary excretion have stimulated great interest. Thus, 
methylglyoxal, a highly reactive AGE precursor molecule, is 
detoxified by glyoxalase I and II. Its reduction can be cata-
lyzed by aldehyde reductase, aldose reductase and carbonyl 
reductase. While, a group of circulating proteins such as 
lysozyme, defensins and lactoferrin can bind AGEs, prevent-
ing them from causing cellular toxicity or from binding to 
other molecules [12, 104, 106]. Consequently, the use of 
antiglycation agents, AGEs crosslink breakers, including 
alagebrium, benfotiamin, aminoguanidine, carnosine may be 
considered as future therapeutic approaches to improve en-
dothelial function, vascular reactivity and cardiac hemody-
namics in diabetic patients [106, 155-157]. Another treatment 
strategy has been recently suggested that involves the in-
crease in AGER1 function (the chief endocytic AGE recep-
tor), which inhibits the function of RAGEs and may provide 
protection against the destructive effect of a chronically high 
OS state such as in DM [12, 13, 106]. 
  Over the past three decades, many in vivo studies have 
been performed utilizing exogenous antioxidants in experi-
mental diabetic models. The beneficial effects of this form of 
treatment on OS can be measured by certain observable 
biomarkers. These markers include the enzymatic activities 
of catalase, SOD, GSH-Px, GR and TBARS levels. The indi-
rect measurement of free-radical production can also be 
undertaken, i.e., malondialdehyde (MDA) and F2-Isopro- 
stanes, and more recently 4-hydroxynonenal, which has been 
shown to be consistently elevated in DM [11, 108, 117, 158]. 
Normalization of the activity of any of these markers, and 
ultimately, the balance of free-radical production/removal, 
would be an effective method to reduce ROS-induced dam-
age. Many animal studies have been conducted with this aim 
in mind and indeed have shown that diabetes-induced altera-
tions of OS indicators can be reversed when the animals are 
treated with various antioxidants. 
  Experiments from “the ADIC Study Group”, observed 
the effectiveness of exogenous antioxidant treatments in the 
recovery of OS markers and endogenous antioxidant enzyme 
activities in STZ-diabetic rats [22, 63, 64, 154, 159-161]. These 
recoveries were associated with the amelioration in vascular 
and cardiac metabolism/function [22, 46, 63, 64, 69, 95, 119, 
142, 147, 148, 154, 159-161]. We have previously focused 
on investigating the effects of dietary supplementation of the 
antioxidants vitamin E, alpha-lipoic acid and vitamin A. 
0.5% dietary vitamin E (DL-alpha tocopheryl acetate) sup-
plementation given to STZ-diabetic rats eliminated the ac-
cumulation of lipid peroxides and returned plasma triglyc-
erides toward normal levels. In addition, diabetes-induced 
abnormal aortic contractility and endothelial dysfunction 
were significantly but not completely prevented by vitamin E 
treatment. It also protected the morphological integrity of the 
diabetic aorta [63]. Vitamin E treatment (400-500 IU/kg/day) 
prevented protein glycation, and Ca
2+accumulation in STZ-
diabetic rats [46] and gluthation-dependent antioxidant de-
fense in the aorta and/or heart and did not affect the de-
creased activity of G-6PD, 6-PGD in diabetic aorta [148]. It 
also restored isoprenaline-stimulated relaxation, as well as, 
structural and metabolic alterations in the diabetic aorta [95]. 
Other actions of this antioxidant include; the prevention of 
(1) capillary basement membrane thickening, vascular endo-
thelial growth factor expression and aldose reductase en-
zyme activity in retina of diabetic rats [161], (2) Ca
2+-
ATPase activity, protein glycosylation and/or Ca
2+ levels in 
the brain [162] and in the kidney [163], ameliorates impaired 
sympathetic neurotransmission and the contractility of iso-
lated vas deferens [160], protects nerve blood flow and con-
duction velocity [164, 165]. In general, studies with vitamin 
E showed that it protects vascular endothelium and cardiac 
function in experimental models of DM [166, 167]. Studies 
on the effect of vitamin E supplementation and deprivation 
in diabetic patients have also been undertaken [168]. Al-
though plasma vitamin E levels was significantly lower in 
poorly controlled NIDDM patients with coronary heart dis-
ease, small clinical trials revealed the beneficial cardiovascu-
lar effect of vitamin E supplementation [169-172]. In a dou-
ble-blind, placebo-controlled, randomized study, vitamin E 
supplementation (1000 IU/day) given to IDDM patients for 
three months significantly improved endothelium-dependent 
vasorelaxation [170]. Similarly, in another study the admini-
stration of vitamin E (800 IU/day) and C (1000 mg/day) in 
combination for six months had a positive effect on endothe-
lium-dependent vasorelaxation in IDDM patients but had no 
effect in NIDDM [171]. Results from the HOPE trial, inves-
tigating myocardial infarction, stroke and death from CVD 
in diabetic patients 55 years of age or older was published in 
2000, it found no significant difference in the primary out-
come between vitamin E and placebo treated groups [172]. A 
recent randomized trial reported that there was no significant 
overall effects of treatment with vitamin C + vitamin E + 
beta-carotene on the risk of developing NIDDM in patients 
at high risk of CVD [173]. However, another recent clinical 
study suggest that supplementation with vitamin E accompa-
nied by a change in lifestyle might help to reduce the dam-
age brought about by free radical toxicity in DM [174]. An-
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of alpha and gamma isomers of vitamin E demonstrated that 
at every dose of alpha vitamin E, gamma vitamin E concen-
tration was significantly suppressed. It was thought that if a 
standardized preparation of gamma vitamin E (without the 
alpha isomer) became available it may be useful in the pre-
vention of atherosclerosis in NIDDM patients [175]. 
  Alpha lipoic acid (ALA; thioctic acid) is another impor-
tant chemical with antioxidant properties that can be used in 
DM studies. ALA scavenges OH radical, HOCl and singlet 
oxygen. It can also exert antioxidant effects in biological 
systems through transitional metal chelation. In its reduced 
form dihydrolipoic acid (DHLA) it is not only an antioxidant 
but also has pro-oxidant properties in systems where OH 
radicals are generated. Thus, the ALA/DHLA ratio helps to 
recycle endogenous antioxidants such as vitamin E [176, 
177]. We found that, ALA treatment (50 mg/kg/day) effec-
tively reversed body weight, blood glucose, plasma insulin, 
cholesterol, triglycerides and lipid peroxidation levels of 12 
weeks STZ-diabetic rats. In addition, it partially improves 
blood pressure, catalase activity and tissue morphology and 
completely reversed the contractile effect of phenylephrine 
in diabetic aorta [64]. In another study, we showed that ALA 
treatment also partially reverse SOD-induced relaxation, 
which is probably related to the elimination of O2
 and   
H2O2, mediating the recovery of basal EDRF/NO availability 
[119]. The potency of ALA in reversing hypertension due to 
an effect on vascular reactivity and tissue morphology, as 
well as, its general metabolic actions in diabetic rats, con-
firms the importance of hyperglycemia-induced OS in the 
development of diabetes-induced vascular complications 
[178, 179]. The metabolic and hemodynamic sequela insulin-
deficiency in the heart is also corrected by ALA [180]. ALA 
reduces OS in STZ-induced diabetic rats by modulating the 
thiol status of the cells [177, 180], thus, preventing high glu-
cose-induced receptor death and mitochondriondependent 
cardiac apoptosis [181], it also increases HSP60 and de-
creases 4-HNE in diabetic heart [182]. Clinical trials with 
ALA have focused on the treatment of diabetic neuropathy, 
the results obtained are more promising than those with vi-
tamin E. Pharmacodynamic studies have shown that ALA 
favorably influences the vascular abnormalities of diabetic 
polyneuropathy, such as impaired microcirculation, the in-
creased indices of OS and increased levels of markers for 
vascular dysfunction, such as thrombomodulin, albuminuria, 
and NF-KB [183, 184]. Thus far, seven controlled random-
ized clinical trials giving ALA to patients with diabetic pe-
ripheral and cardiac autonomic neuropathy have been com-
pleted; (Alpha-Lipoic Acid in Diabetic Neuropathy [ALA-
DIN I-III] [185, 186], Deutsche Kardiale Autonome Neuro-
pathie [DEKAN] [187], Oral Pilot [ORPIL] [188], Sympto-
matic Diabetic Neuropathy [SYDNEY] [189], Neurological 
Assessment of Thioctic Acid in Neuropathy [NATHAN I- II] 
[190]. These studies have used different; study designs, 
treatment duration, doses, sample sizes, and patient popula-
tion. They have revealed the efficacy and safety of thioctic 
acid (600 mg intravenously for 3 weeks) in diabetic patients 
with symptomatic polyneuropathy [184, 191]. 
  We demonstrated that 12 weeks STZ-diabetes caused a 
reduction in plasma retinol and retinol-binding protein 
(RBP), which was significantly improved by insulin therapy 
(8-10 IU/rat/day s.c), whereas, vitamin A (retinol acetate, 30 
mg/kg/day i.o) treatment failed to increase plasma retinol 
and RBP levels. These findings suggest that the combination 
of insulin with vitamin A provides more benefit than either 
agent alone in the treatment of the general characteristics of 
DM and that the maintenance of the antioxidant defense of 
the diabetic heart can reduce peroxidative stress-induced 
cardiac injury [147]. In addition, our findings suggest that 
the maintenance of ACh-stimulated endothelium-dependent 
vasorelaxant tone within normal physiological levels de-
pends largely on the prevention and/or inhibition of peroxi-
dative stress, and that the use of vitamin A together with 
insulin provides better metabolic control with a reduction in 
diabetes-induced vascular complications than when insulin is 
used alone [154]. Vitamin A is also an ingredient of the Cod 
Liver Oil (CLO). CLO is mainly comprised of; omega-3 
polyunsaturated fatty acids (PUFAs), eicosapentaenoic acid 
(EPA) and docosahexaenoic acid (DHA) as well as vitamin 
A. CLO treatment caused significant improvements in hyper-
lypidemia and glucose metabolism, allowing the recovery of 
the normal growth rate of STZ-diabetic rats. It also amelio-
rated OS/peroxidative stress and endogenous antioxidant 
enzyme activities in the heart and blood vessels [22, 159]. In 
addition, CLO treatment also completely prevented endothe-
lial deficiency and partially corrected the phenylephrine-
induced vasoconstriction of diabetic aorta. The impaired 
responsiveness of the right atria to the positive chronotropic 
effect of isoprenaline and noradrenaline and the positive 
inotropic effect of the papillary muscle to both agents, and 
abnormal ultrastructure of cardiomyoctes were also signifi-
cantly ameliorated by CLO [22, 159]. Several reports have 
shown that a combination of antioxidants may be superior to 
the use of monotherapy. 
  The Steno-2 trial compared the effect of a multifactorial 
intensive therapy (n=80) with that of conventional treatment 
(n=80) on modifiable risk factors for CVD in patients with 
NIDDM. The patients received pharmacotherapy that tar-
geted hyperglycemia, dyslipidemia, hypertension and micro-
albuminuria including daily supplementation of vitamin C 
(250 mg), E (100 mg), folic acid (400 mg) and chromium 
picolinate (100 mg), as well as, behavioral modification in-
cluding; low-fat diet, exercise and smoking cessation. The 
control group received conventional therapy as recom-
mended by national guidelines. The intensive therapy re-
sulted in almost a 50% decrease in the risk of cardiovascular 
events, providing evidence that a multifactorial approach is 
superior to conventional therapy for the prevention of OS-
induced vascular complications in DM [192]. However, a 
more recent trial (POPADAD) does not provide evidence to 
support the use of aspirin or antioxidants in the primary pre-
vention of cardiovascular events and mortality in the diabetic 
population studied [193]. Treatment with Zycose, a new 
compound, provided therapeutic benefit believed to be due 
to its additive effects with other drugs; lowering homocys-
teine levels (folic acid), reducing the production of advanced 
glycation end products (benfotiamine), improving endothe-
lial function (folic acid, benfotiamine, ALA), reducing oxi-
dative stress (ALA, vitamin E) and reducing carbonyl stress 
(benzamine) [194]. 
  Probucol is another antioxidant compound used in ex-
perimental DM to determine its effect on cardiovascular 
function. Treatment with this antioxidant prevented lipid 
abnormalities, sorbitol pathway enzymes and nerve blood 
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effectiveness of probucol was more apparent when used in 
combination with essential fatty acids (evening primrose oil) 
[164]. Short term probucol treatment (300 mg/kg/day, i.o.) 
also resulted in partial restoration of endothelial function and 
noradrenaline-induced contraction in aorta without any al-
terations in morphological abnormalities in STZ-diabetic rats 
[68]. Essentially, probucol is a diphenolic compound that 
reduces atherosclerosis and restenosis probably through anti-
hyperlypidemic, anti-inflammatory and anti-oxidant proper-
ties [150]. It also preserves pancreatic beta-cell function 
through a reduction of OS in diabetic patients [195, 196]. 
  In addition to the antioxidants mentioned above, a num-
ber of commonly used drugs have been reported to have an-
tioxidant activity, in addition to their primary pharmacologi-
cal property. For example, gemfibrozil, a lipid lowering fi-
brate, was previously reported to have antioxidant actions 
[197]. However, although it reduced lipid peroxidation, it did 
not alter blood glucose or tissue antioxidant enzymes in 
chronically diabetic rats [198]. This suggests that the benefi-
cial effect of short-term gemfibrozil treatment in reducing 
lipid peroxidation, endothelial dysfunction and vascular re-
activity are attributed to its effect on circulating lipids [198, 
199]. Antihyperlipidemic statins are thought to exert an anti-
oxidant effects via a variety of mechanisms. Statin therapy 
(10 mg/kg/day,orally) markedly reduces OS markers and 
ultra structural impairments in diabetic rat myocardium 
[142]. It also ameliorated diabetes-induced vascular abnor-
mal vasoconstriction and endothelial dysfunction via an af-
fect on; oxidizing metabolism, NO bioavailability and intra-
cellular Ca
2+ mobilization [143]. In addition, we have deter-
mined the vascular effect of thiazolidinediones, using human 
internal mammary artery, human saphenous vein and dia-
betic rat aorta in vitro [73, 200, 201], the beneficial effect 
were, at least in part linked with their antioxidant properties, 
similar to those shown in diabetic animals [202]. 
BENEFICIAL EFFECTS OF PYRIDOINDOL ANTI-
OXIDANTS IN DM 
  Numerous studies have proven that stobadine (STB), a 
novel synthetic pyridoindole, is an efficient antioxidant 
[203]. During the last decade, in collaboration with the Slo-
vak Academy of Sciences, we examined the antioxidant 
properties of STB and related pyridoindole derivatives. The 
protective effect of STB against glycoxidative damage using 
an in vitro experimental glycation model has been reported 
[204]. STB also attenuated diabetes-induced pathological 
changes in various organs, decreased albuminuria, enzy-
muria, lipid peroxidation and matrix collagen cross-linking 
[205]. In addition, it reduced plasma cholesterol and triglyc-
eride levels in STZ-diabetic rats [46, 206] Recently, we 
showed that STB caused a significant decrease in protein 
carbonylation, advanced oxidation protein products and 
normalized protein thiol, total thiol, non-protein thiol groups 
in the liver of diabetic animals [207]. The combination of 
STB with vitamin E was beneficial in reducing hyperglyce-
mia and lipid peroxidation in diabetic animals. The anti-
hyperglyceamic effect of these antioxidants may be due to 
the early stabilization of the pancreas beta cell membrane. 
These antioxidants may partially protect insulin-secreting 
cells against the detrimental effects of free radicals when 
given at the onset of diabetes or promptly after STZ injection 
[46]. STB was also able to control the glycation of hemoglo-
bine, determined by HbA1c levels, which was significantly 
decreased by long-term STB treatment of chronically STZ-
diabetic rats [160]. STZ-diabetic rats, orally treated with a 
low dose of STB (24.7 mg/kg/day), showed an inhibition in 
cardiac protein glycation and Ca
2+ accumulation. These ef-
fects were associated with decreased plasma lipid peroxida-
tion. However, STB treatment did not influence the diabetes-
induced inhibition of cardiac Ca
2+,Mg
2+-ATPase activity 
[46]. This is supported by the finding that long term STB 
treatment prevents diabetes-induced deterioration of cardiac 
Na
+,K
+-ATPase [208] and reduces oxidative damage of 
myocardial tissue, as measured by conjugated dienes. It also 
reverses myocardial levels of alpha-tocopherol and coen-
zyme Q9 to near control values. Moreover, it attenuates the 
elevated activity of SOD and diminishes angiopathic and 
atherogenic processes in diabetic myocardium [206-208]. 
Diabetes-induced stimulation of cardiac GSH-Px activity and 
inhibition of cardiac GR activity was prevented by STB 
treatment [148]. These findings suggest that the cardiopro-
tective effect of STB is more complex than its preservation 
of mitochondrial function [209].  
  The combination of STB and vitamin E provided more 
benefits than each individual therapy alone in the reduction 
of lipid peroxidation and cardiac abnormalities in diabetic 
animals [46]. This was evident in the; kidney, brain [148], 
liver [46], peripheral nerves [160, 164] and retina of diabetic 
rats [161]. Interestingly, the increase in retinal capillary 
basement membrane thickness (RCBMT) was 12.34% in 
diabetic rats treated with STB and 23.07% in diabetic rats 
treated with vitamin E. While, the increase in RCBMT was 
just 4.38% following combination therapy [161]. However, 
combination therapy did not protect against leukocyte free 
radical production, while STB alone had a significant protec-
tive effect on leukocyte function [210]. Although STB and 
vitamin E produces parallel effects on the preservation/ 
restoration of the pro-oxidant feature of DM and generally 
has similar characteristics in the protection of tissue func-
tion; some differences have also been observed. For instance, 
while the in vivo administration of vitamin E alone had no 
effect, STB treatment completely returned noradrenaline-
induced contractions to basal levels in diabetic vas deferens 
[160]. The effect of long term treatment with STB or vitamin 
E in the development of cataracts in diabetic animals has 
also been investigated. Interestingly, at the end of the ex-
perimental period, the visual cataract score was significantly 
decreased in the diabetic groups treated with STB, while 
vitamin E had no significant effect [211]. It is conceivable 
that an antioxidant given alone in vivo would be more effec-
tive when other antioxidants are present. It is well known 
that alpha-tocopherol can recycle stobadine [212], thus the 
antioxidant potency of stobadine in vivo may be increased by 
its interaction with other antioxidants [213]. We anticipated 
that stobadine given in a mixture with vitamin E would have 
enhanced antioxidant and anticataract action when given to 
diabetic rats. However, contrary to our expectation, com-
bined treatment with STB + vitamin E accelerated the pro-
gression of cataract, without affecting the overall visual cata-
ract score. Moreover, biochemical analysis showed a further 
decrease of lens protein free sylfhydryls in diabetic rats 
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untreated diabetic group, indicating a prooxidant effect of 
the STB + vitamin E cocktail [212, 213]. Similar observa-
tions are in the literature showing that individually taken 
vitamin E, C, or A was effective in reducing cataract risk, 
while the combination of the three supplements potentiated 
cataract formation [214].  
  The effects of STB on vascular function have been 
largely studied at different stages of STZ-diabetes. Satnikova 
et al. reported that 8-month STB supplementation to diabetic 
rats resulted in the protection of aortic function and ultra-
structure; evaluated by aortic reactivity to noradrenaline, 
ACh and H2O2 under isometric conditions and transmission 
electron microscopy, respectively [215]. We found that STB 
treatment significantly reduced phenylephrine and BayK 
8644-induced contractions in diabetic rats compared to con-
trol and untreated-diabetic rats. Neither DM nor STB treat-
ment changed the vascular reactivity to KCl and CaCl2. Dia-
betes-induced decrease in vascular relaxation to ACh was 
ameliorated by STB treatment and STB partially controlled 
mean arterial blood pressure in diabetic rats. These observa-
tions support the findings that increased entry of Ca
+2 medi-
ates elevated contraction to BayK 8644 and phenylephrine in 
diabetic aorta and the inhibitory effect of in vivo STB treat-
ment on Ca
+2 entry through cytosolic membrane-bound Ca
+2 
channels may account for its reducing effectiveness on the 
vasoconstriction and blood pressure. A23187-induced 
vasorelaxation was markedly inhibited in STB-treated dia-
betic rats compared with control and untreated-diabetic rats. 
The inhibitory effect of STB on Ca
+2 influxes in endothelial 
cells may account for its reduced effect on A23187-
stimulated relaxations [69]. These results are also in agree-
ment with the Ca
+2 mobilization regulating effect of STB on 
membranes [216-218] and support our previous findings, 
which demonstrated an inhibitory effect of STB on intracel-
lular Ca
+2 accumulation in diabetic heart and liver [56]. STB 
also exerts a protective effect through free radical-scavenging 
and anti-oxidant activities in the ischemia/reperfusion injury 
model, as previously reported [218-220]. More recently, we 
have focused on evaluating the effects of STB and other an-
tioxidant pyridoindoles [221] using transformed and non-
transformed cells. Pre-treating cells with STB significantly 
increased cell viability and decreased apoptosis rate; deter-
mined by flow cytometric analysis and by measuring 
caspase-3 and caspase-9 activities in doxorubicin-induced, 
free radical-mediated apoptosis model of P815 cells [222]. 
We have also suggested that STB and its analogues protect 
insulin release in the INS 1E-cell line exposed to H2O2 or 
cytokine cocktail and that the antioxidant effects of pyrido-
indoles also mediate antiapoptotic processes via intrinsic as 
well as extrinsic pathway of programmed cell death in insu-
lin releasing cells. This may provide an appropriate explana-
tion for the decrease in severity of hyperglycemia caused by 
STB, which might have therapeutic implications in the pre-
vention of autoimmune DM [223]. Interestingly, a derivative 
of STB, suppressed the intracellular generation of ROS, re-
duced cell swelling, improved the reduced cell proliferation 
and viability was not able to suppress protein carbonyl for-
mation in HT22 neuronal cells under glucose toxicity [224]. 
CONCLUSION 
  Several mechanisms have been proposed to explain the 
harmful effects of glucose. Glucose could be directly toxic to 
cell components because it can promote non-enzymatic   
glycosylation and the accumulation of AGEs, which impair 
cellular functions and mediate an increase in the production 
of ROS. In the presence of elevated glucose metabolism, the 
excessive production of electrons can promote the generation 
of ROS; if there is not a matching increase in the efficiency 
of electron transport system, this can lead to GOS and cellu-
lar injury in the long term. Although, multiple biochemical 
pathways are likely to be responsible for diabetic cardiovas-
cular complications, substantial evidence suggests a key role 
for GOS. Therefore, recent interest has focused on strategies 
to prevent, reverse or retard GOS in order to modify the 
natural history of diabetic CVD. Even though, there is an 
increasing amount of experimental evidence showing the 
beneficial effects of antiglycoxidative (antioxidant) agents in 
the prevention/treatment of diabetic CV abnormalities, some 
clinical trials conducted to date, failed to provide adequate 
support for the use of antioxidant therapy in DM. However, 
it is still too early to reach a definitive conclusion on the 
clinical benefits of antioxidants. It is possible that antioxi-
dants would be more demonstrably effective in a patient 
population chosen on the basis of elevated levels of GOS. 
Unfortunately, none of the studies to date effectively as-
sessed the baseline GOS at the time of patient recruitment. 
The clinical trials generally used endpoints that were not 
directly related to GOS, but rather gross markers of overall 
cardiovascular health, such as effect on mortality. In the 
evaluation of GOS/OS and the effects of antioxidants 
thereon, specific markers should be measured. We strongly 
believe that more research on the use of antioxidants 
(antiglycoxidative agents) in the prevention of diabetic car-
diovascular complications is necessary and should be en-
couraged. Pharmacological intervention using different anti-
oxidants may have significant implications in the prevention 
of the pro-oxidant feature of DM and protect the redox status 
of the cardiovascular cells. Finally, the search for novel anti-
oxidant/antiglycoxidative agents with enhanced efficiency, 
optimized bioavailability, reduced adverse effects and de-
creased toxicity should be continued, with the prospect of 
preventing, or delaying long-term cardiovascular diabetic 
complications. 
ABBREVIATIONS 
Ach =  Acetylcholine   
AR  =  Adrenergic receptor  
AGEs  =  Advanced glycation end products  
ACE =  Angiotensin-converting  enzyme 
alpha AR  =  Alpha-adrenergic receptor 
ALA =  Alpha  lipoic  acid 
RONOO =  Alkyl  peroxynitrates 
beta-Ars =  Beta-adrenergic  receptors 
CLO =  Cod  Liver  Oil 
cAMP  =  Cyclic adenosine monophosphate  
cGMP  =  Cyclic guanosine monophosphate  
DM =  Diabetes  mellitus   
DAG =  Diacylglycerol Glycoxidative Stress and Cardiovascular Complications  The Open Cardiovascular Medicine Journal, 2010, Volume 4    251 
DHLA =  Dihydrolipoic  acid 
DHA =  ocosahexaenoic  acid 
EPA =  Eicosapentaenoic  acid 
eNOS  =  Endothelial nitric oxide synthase 
ET =  Endothelin 
EDHF =  Endothelium-dependent  hyperpolarization 
EDRF  =  Endothelium-derived relaxing factor 
FAD  =  Flavin adenine dinucleotide 
FMN =  Flavin  mononucleotide 
G-6PD =  Glucose-6-phosphate  dehydrogenase 
GOS =  Glycoxidative  stress 
GSH-Px =  Glutathione  peroxidase 
GR  =  Glutathione reductase  
HOCl =  hydrochlorous  acid 
H2O2 =  Hydrogen peroxide 
HRO2 =  Hydroperoxyl 
HNO2 =  Nitrous oxide 
IDDM  =  Insulin-dependent diabetes mellitus  
IL-6 =  interleukin-  6 
LVDP  =  Left ventricular developed pressure 
L-NAME  =  L-nitro-arginine methyl ester 
MDA =  Malondialdehyde 
MCP-1 =  Monocyte  chemoattractant  protein 
NADPH  =  Nicotinamide adenine dinucleotide phos-
phate 
NO =  Nitric  oxide 
NOS  =  Nitric oxide synthase 
NO2 =  Nitrogen  dioxide 
NIDDM  =  Non-insulin-dependent diabetes mellitus  
NF-KB =  Nuclear  factor-kappaB 
OS =  Oxidative  stress 
ONOO =  Peroxynitrite 
OH =  Hydroxyl 
PDE5 =  Phosphodiesterase  type  5 
PUFAs  =  Omega-3 polyunsaturated fatty acids 
PKC  =  Protein kinase C  
ROS  =  Reactive oxygen species  
RNS  =  Reactive nitrogen species  
RAGE  =  Receptor advanced glycation end products 
RCBMT  =  Retinal capillary basement membrane 
thickness 
RBP =  Retinol-binding  protein 
RO2 =  Peroxyl   
STB =  Stobadine   
STZ =  Streptozotocin 
SOD =  Superoxide  dismutase 
O2 =  Superoxide 
TBARS  =  Thiobarbituric acid reactive substances 
VCAM-1 = Vascular  cellular  adhesion  molecule-1   
6-PGD =  6-phosphogluconate  dehydrogenase 
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